Literature DB >> 24518794

The metabolic evaluation of the child with an intellectual developmental disorder: diagnostic algorithm for identification of treatable causes and new digital resource.

Clara D M van Karnebeek1, Michael Shevell2, Johannes Zschocke3, John B Moeschler4, Sylvia Stockler5.   

Abstract

Intellectual developmental disorders (IDD), characterized by significant impairment of cognitive functions, with limitations of learning, adaptive behavior and skills, are frequent (2.5% of the population affected) and present with significant co-morbidity. The burden of IDD, in terms of emotional suffering and associated health care costs, is significant; prevention and treatment therefore are important. A systematic literature review, updated in 2013, identified 89 inborn errors of metabolism (IEMs), which present with IDD as prominent feature and are amenable to causal therapy. Therapeutic effects include improvement and/or stabilization of psychomotor/cognitive development, behavior/psychiatric disturbances, seizures, neurologic and systemic manifestations. The levels of available evidence for the various treatments range from Level 1b, c (n=5); Level 2a, b, c (n=14); Level 4 (n=53), and Levels 4-5 (n=27). For a target audience comprising clinical and biochemical geneticists, child neurologists and developmental pediatricians, five experts translated....this data into a 2-tiered diagnostic algorithm: The first tier comprises metabolic "screening" tests in urine and blood, which are relatively accessible, affordable, less invasive, and have the potential to identify 60% of all treatable IEMs. The second tier investigations for the remaining disorders are ordered based on individual clinical signs and symptoms. This algorithm is supported by an App www.treatable-id.org, which comprises up-to-date information on all 89 IEMs, relevant diagnostic tests, therapies and a search function based on signs and symptoms. These recommendations support the clinician in early identification of treatable IEMs in the child with IDD, allowing for timely initiation of therapy with the potential to improve neurodevelopmental outcomes. The need for future studies to determine yield and usefulness of these recommendations, with subsequent updates and improvements to developments in the field, is outlined.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Algorithm; App; Cognition; Diagnosis; Inborn errors of metabolism; Treatable

Mesh:

Year:  2014        PMID: 24518794     DOI: 10.1016/j.ymgme.2014.01.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  41 in total

1.  AIMP1 deficiency presents as a cortical neurodegenerative disease with infantile onset.

Authors:  L Armstrong; R Biancheri; C Shyr; A Rossi; G Sinclair; C J Ross; M Tarailo-Graovac; W W Wasserman; C D M van Karnebeek
Journal:  Neurogenetics       Date:  2014-06-24       Impact factor: 2.660

2.  Exome Sequencing and the Management of Neurometabolic Disorders.

Authors:  Maja Tarailo-Graovac; Casper Shyr; Colin J Ross; Gabriella A Horvath; Ramona Salvarinova; Xin C Ye; Lin-Hua Zhang; Amit P Bhavsar; Jessica J Y Lee; Britt I Drögemöller; Mena Abdelsayed; Majid Alfadhel; Linlea Armstrong; Matthias R Baumgartner; Patricie Burda; Mary B Connolly; Jessie Cameron; Michelle Demos; Tammie Dewan; Janis Dionne; A Mark Evans; Jan M Friedman; Ian Garber; Suzanne Lewis; Jiqiang Ling; Rupasri Mandal; Andre Mattman; Margaret McKinnon; Aspasia Michoulas; Daniel Metzger; Oluseye A Ogunbayo; Bojana Rakic; Jacob Rozmus; Peter Ruben; Bryan Sayson; Saikat Santra; Kirk R Schultz; Kathryn Selby; Paul Shekel; Sandra Sirrs; Cristina Skrypnyk; Andrea Superti-Furga; Stuart E Turvey; Margot I Van Allen; David Wishart; Jiang Wu; John Wu; Dimitrios Zafeiriou; Leo Kluijtmans; Ron A Wevers; Patrice Eydoux; Anna M Lehman; Hilary Vallance; Sylvia Stockler-Ipsiroglu; Graham Sinclair; Wyeth W Wasserman; Clara D van Karnebeek
Journal:  N Engl J Med       Date:  2016-05-25       Impact factor: 91.245

3.  Expansion of the QARS deficiency phenotype with report of a family with isolated supratentorial brain abnormalities.

Authors:  Ramona Salvarinova; Cynthia X Ye; Andrea Rossi; Roberta Biancheri; Elke H Roland; Paul Pavlidis; Colin J Ross; Maja Tarailo-Graovac; Wyeth W Wasserman; Clara D M van Karnebeek
Journal:  Neurogenetics       Date:  2014-11-30       Impact factor: 2.660

4.  Early identification of treatable inborn errors of metabolism in children with intellectual disability: The Treatable Intellectual Disability Endeavor protocol in British Columbia.

Authors:  Clara Dm van Karnebeek; Sylvia Stockler-Ipsiroglu
Journal:  Paediatr Child Health       Date:  2014-11       Impact factor: 2.253

5.  The role of integrated behavioral health in caring for patients with metabolic disorders.

Authors:  Neelkamal Soares; Roger W Apple; Shibani Kanungo
Journal:  Ann Transl Med       Date:  2018-12

6.  Genetic Approach to Diagnosis of Intellectual Disability.

Authors:  Ratna Dua Puri; Moni Tuteja; I C Verma
Journal:  Indian J Pediatr       Date:  2016-09-13       Impact factor: 1.967

7.  Brief Report: Delayed Diagnosis of Treatable Inborn Errors of Metabolism in Children with Autism and Other Neurodevelopmental Disorders.

Authors:  María Elena Márquez-Caraveo; Isabel Ibarra-González; Rocío Rodríguez-Valentín; Miguel Ángel Ramírez-García; Verónica Pérez-Barrón; Eduardo Lazcano-Ponce; Marcela Vela-Amieva
Journal:  J Autism Dev Disord       Date:  2021-06

Review 8.  Unexplained developmental delay/learning disability: guidelines for best practice protocol for first line assessment and genetic/metabolic/radiological investigations.

Authors:  J J O'Byrne; S A Lynch; E P Treacy; M D King; D R Betts; P D Mayne; F Sharif
Journal:  Ir J Med Sci       Date:  2015-04-21       Impact factor: 1.568

Review 9.  Delivery of epilepsy care to adults with intellectual and developmental disabilities.

Authors:  Orrin Devinsky; Miya Asato; Peter Camfield; Eric Geller; Andres M Kanner; Seth Keller; Michael Kerr; Eric H Kossoff; Heather Lau; Sanjeev Kothare; Baldev K Singh; Elaine Wirrell
Journal:  Neurology       Date:  2015-09-30       Impact factor: 9.910

Review 10.  A roadmap for precision medicine in the epilepsies.

Authors: 
Journal:  Lancet Neurol       Date:  2015-09-20       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.